Latest Articles

Comercial Manufacturing site in Philadelphia

February 20, 2024

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI^™ (lifileucel) for Advanced Melanoma

WuXi Advanced Therapies announced FDA approval of its Philadelphia site for commercial manufacturing and testing of Iovance's AMTAGVI™ which received accelerated approval of its BLA on February 16.

All articles

November 8, 2023

WuXi Advanced Therapies Supports First Investigational CD19 CAR-T Therapy Approved by China’s NMPA

August 22, 2023

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

WuXi Advanced Therapies Cabaletta CABA-201

June 6, 2023

WuXi ATU and T-MAXIMUM Announce Strategic Partnership of Cooperation for MT-027 UCAR-T

March 16, 2023

Clinical Phase I/II IND Approval! The first cell therapy project in Korea supported by WuXi Advanced Therapies receives MFDS approval

WuXi Advanced Therapies Ticaros Approval

August 12, 2022

WuXi Advanced Therapies Announces Licensing Agreement with Janssen

WuXi Advanced Therapies TESSA AAV Janssen

January 7, 2022

WuXi Advanced Therapies Testing Facility To Receive EMA GMP Certificate for New Philadelphia Facility

WuXi Advanced Therapies R400 Philadelphia

Upcoming Events

Jun 17

Boston, Massachusetts

Immunotherapies Xchange – Boston 2025

Jun 19

London, UK

BSGCT Annual Conference 2025

Jun 24

Gothenburg, Sweden

PDA Virus Conference 2025

See All Events

Resources

Gain access to white papers, posters, videos, case studies, brochures and more.

Access All Resources